Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Impact of CancelRx on Discontinuation of Controlled Substance Prescriptions

View ORCID ProfileTaylor L. Watterson, Jamie A Stone, Aaron Gilson, Roger Brown, Ka Z Xiong, Anthony Schiefelbein, Edmond Ramly, Peter Kleinschmidt, Michael Semanik, Lauren Craddock, Samantha Pitts, Taylor Woodroof, View ORCID ProfileMichelle Chui
doi: https://doi.org/10.1101/2021.01.12.21249700
Taylor L. Watterson
1University of Wisconsin-Madison School of Pharmacy, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Taylor L. Watterson
Jamie A Stone
1University of Wisconsin-Madison School of Pharmacy, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron Gilson
1University of Wisconsin-Madison School of Pharmacy, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Brown
2University of Wisconsin-Madison School of Nursing, Madison, WI, USA
4University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ka Z Xiong
3Wisconsin Department of Health Services, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Schiefelbein
2University of Wisconsin-Madison School of Nursing, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edmond Ramly
4University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
5University of Wisconsin-Madison College of Engineering, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Kleinschmidt
4University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Semanik
4University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Craddock
6Compass Dermatopathology, Inc., San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Pitts
7Johns Hopkins Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taylor Woodroof
7Johns Hopkins Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Chui
1University of Wisconsin-Madison School of Pharmacy, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michelle Chui
  • For correspondence: michelle.chui@wisc.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective To assess how controlled substance medication discontinuations were communicated over time

Data Sources Secondary data from a midwestern academic health system electronic health record and pharmacy platform were collected 12-months prior to CancelRx implementation and for 12-months post implementation.

Study Design The study utilized an interrupted time series analysis (ITSA) to capture the proportion of controlled substance medications that were cancelled in the clinic’s electronic health record and also cancelled in the pharmacy’s dispensing software. The ITSA plotted the proportion of successful cancellation messages over time, particularly after the health system’s implementation of CancelRx, a novel technology.

Data Collection/Extraction Data were extracted from the EHR and pharmacy records for patients aged 18+ who had a controlled substance discontinued by a health system provider. Information collected included patient demographics, drug information (name, dose), and dates discontinued in the clinic and pharmacy records.

Principal Findings After CancelRx implementation there was a significant increase in the proportion of discontinued controlled substance medications that were communicated to the pharmacy.

Conclusions This study demonstrates the role that technology can play in promoting controlled substance policy and medication safety.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This project was supported by the National Council for Prescription Drug Programs (NCPDP) Foundation, Gordon and Betty Moore Foundation, ID: GBMF6990; Agency for Healthcare Research and Quality, ID: R21HS025793. The project described was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR002373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Support for this research was provided by the University of Wisconsin - Madison Office of the Vice Chancellor for Research and Graduate Education with funding from the Wisconsin Alumni Research Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the University of Wisconsin-Madison Institutional Review Board.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data underlying this article cannot be shared publicly for the privacy of individuals that participated in the study; the dataset contains protected health information. The data underlying this article were provided by UW Health by permission. Data will be shared on reasonable request to the corresponding author with permission of UW Health.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 15, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Impact of CancelRx on Discontinuation of Controlled Substance Prescriptions
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Impact of CancelRx on Discontinuation of Controlled Substance Prescriptions
Taylor L. Watterson, Jamie A Stone, Aaron Gilson, Roger Brown, Ka Z Xiong, Anthony Schiefelbein, Edmond Ramly, Peter Kleinschmidt, Michael Semanik, Lauren Craddock, Samantha Pitts, Taylor Woodroof, Michelle Chui
medRxiv 2021.01.12.21249700; doi: https://doi.org/10.1101/2021.01.12.21249700
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Impact of CancelRx on Discontinuation of Controlled Substance Prescriptions
Taylor L. Watterson, Jamie A Stone, Aaron Gilson, Roger Brown, Ka Z Xiong, Anthony Schiefelbein, Edmond Ramly, Peter Kleinschmidt, Michael Semanik, Lauren Craddock, Samantha Pitts, Taylor Woodroof, Michelle Chui
medRxiv 2021.01.12.21249700; doi: https://doi.org/10.1101/2021.01.12.21249700

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Systems and Quality Improvement
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1090)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9746)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2298)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11618)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2136)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (144)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (692)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (450)
  • Respiratory Medicine (621)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)